Drug Profile
Crotaline snake antivenom - Instituto Bioclon/Rare Disease Therapeutics
Alternative Names: Anavip; Crotalidae immune F(ab)2 (equine); Crotalidae snake antivenom - Instituto Bioclon/Rare Disease TherapeuticsLatest Information Update: 07 Apr 2021
Price :
$50
*
At a glance
- Originator Instituto Bioclon
- Developer Instituto Bioclon; Rare Disease Therapeutics
- Class Antivenins; Fab fragments
- Mechanism of Action Protein inhibitors; Viper venom inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Snake venom poisoning
Most Recent Events
- 05 Apr 2021 The US FDA approves crotaline snake antivenom for Snake venom poisoning (In neonates, In infants, In children, In adolescent, In adults) by North American Pit Vipers including rattlesnake, copperhead and cottonmouth
- 08 Oct 2018 Launched for Snake venom poisoning (In neonates, In infants, In children, In adolescent, In adults) in USA (IV)
- 20 Jun 2005 Phase-II clinical trials in Snake venom poisoning in USA (IV) (NCT00868309)